Cargando…
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestr...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2006.
|
| Edición: | 1st ed. 2006. |
| Colección: | Milestones in Drug Therapy,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-7643-7418-1 | ||
| 003 | DE-He213 | ||
| 005 | 20220120053656.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2006 sz | s |||| 0|eng d | ||
| 020 | |a 9783764374181 |9 978-3-7643-7418-1 | ||
| 024 | 7 | |a 10.1007/3-7643-7418-7 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Aromatase Inhibitors |h [electronic resource] / |c edited by B.J.A. Furr. |
| 250 | |a 1st ed. 2006. | ||
| 264 | 1 | |a Basel : |b Birkhäuser Basel : |b Imprint: Birkhäuser, |c 2006. | |
| 300 | |a IX, 182 p. 30 illus. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 505 | 0 | |a Background and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors. | |
| 520 | |a Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Internal medicine. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Cytology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Internal Medicine. |
| 650 | 2 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Cell Biology. |
| 700 | 1 | |a Furr, B.J.A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783764390525 |
| 776 | 0 | 8 | |i Printed edition: |z 9783764371999 |
| 830 | 0 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/3-7643-7418-7 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||